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Th2-driven responses are instrumental in disease pro-
cesses including allergies, asthma, and helminth infection,
and are characterized by the production of the cytokines
IL-4, IL-5, IL-9, and IL-13. These cytokines form a com-
plex network of molecular and cellular interactions that
mediate protective immunity not only to worm infection,
but also to induce inappropriate inflammatory responses to
allergic challenge. Given the clinical importance of these
molecules, considerable effort has gone into attempting to
identify the relative contributions of the major Th2 cyto-
kines to such disease processes. It has become apparent that
Th2 responses are highly complex and might be regulated
at many levels through a multitude of pathways, including
temporal and spatial regulation of both cytokine and cyto-
kine receptor transcription and translation, so as to initiate
an appropriate defense mechanism as well as return to a
basal level once the infection has been controlled. Thus,
during an immune response certain signals lead to the up-
regulation of cytokine secretion by specific cells whereas
others lead to the expression of the cognate receptors of
these ligands by responding cells, resulting in cellular acti-
vation where ligand and receptor expression coincide.
However, this model is complicated by the existence of
multiple cytokine receptors with overlapping binding spec-
ificities. It is important, therefore, not only to determine
the roles of the individual cytokines, but also the functions
mediated by their receptors.
IL-13 has proven to be an extremely important immu-
noregulator and its direct roles in the generation of disease
pathology has triggered the search for therapeutics capable
of blocking the actions of IL-13 in vivo. Recent investiga-
tions have addressed the functional biology of IL-13 using
in vivo models with defined Th2 responses. Complemen-
tary studies using IL-13 antagonists and IL-13–deficient
mice have demonstrated that ablating IL-13 activity pro-
foundly inhibits the pathophysiology of asthma (1–3) and
impairs the expulsion of parasitic gastrointestinal helminths
(4, 5). Similarly, overexpression of IL-13 in transgenic mice
has highlighted the potentially detrimental responses initi-
ated by this cytokine. As overexpression of IL-13 in mice
leads to a broad disease phenotype it is important that in
normal mice, and presumably in man, the levels of IL-13
are tightly controlled.
The complexity of receptor usage and the potential di-
versity of signaling pathways combine with the temporal
and spatial expression of the individual ligands to create a
diversity of possible responses. The receptor components
that interact with IL-13 are members of the haematopoi-
etin receptor family and display the complexity and pro-
miscuity typical of this family. Indeed, analysis of IL-4 and
IL-13 receptor usage explains many aspects of the overlap-
ping biological responses induced by these related cyto-
kines (Fig. 1). Two IL-13 binding chains have been identi-
 
fied, IL-13R
 
 
 
1 and IL-13R
 
 
 
2, and these are members of
the class I cytokine receptor family. The main structural
 
difference between the two IL-13 receptors is that the
 
IL-13R
 
 
 
1 chain has a longer intracellular domain than
IL-13R
 
 
 
2. IL-13R
 
 
 
1 is a low affinity IL-13 binding chain
 
(kD 
 
 
 
4 nM) that requires the recruitment of IL-4R
 
  
 
into
 
a receptor complex for the formation of a high affinity IL-13
receptor (kD 
 
 
 
30 pM) and the initiation of signal trans-
duction (6, 7). Although both IL-4 and IL-13 can cross-
compete for IL-4R
 
  
 
when it forms part of the IL-4R
 
 
 
–
IL-13R
 
 
 
1 complex, only IL-4 binds directly to IL-4R
 
 
 
(8). As a consequence, the IL-4R
 
 
 
–IL-13R
 
 
 
1 complex
was also identified as a functional IL-4 receptor (9). Al-
though the IL-13R
 
 
 
1–IL-4R
 
  
 
does not have an intrinsic
kinase domain it does initiate a Janus kinase/signal trans-
ducer and activator of transcription signaling cascade result-
ing in the activation of signal transducer and activator of
transcription 6 (10). Further differential signaling pathways
can be envisaged for the IL-4R because IL-4 binding may
recruit IL-13R
 
 
 
1 or IL-2R
 
 
 
c into its active receptor com-
plex (11, 12). The promiscuous IL-2R
 
 
 
c chain, found in
the IL-2, IL-4, IL-7, IL-9, and IL-15 receptors, does not
appear to be a functional component of the IL-13 receptor
(13). IL-13R
 
 
 
2 binds IL-13 with high affinity (kD 
 
 
 
450
pM) without the presence of additional receptor chains
(14–16) and has been engineered to act as a soluble antago-
nist of IL-13 function (15). Although expressed at the cell
surface, the function of IL-13R
 
 
 
2 as a signaling molecule
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remains uncertain. Indeed, it has been suggested that IL-
13R
 
 
 
2 may function as an inhibitor of IL-13 activity and
the existence of a naturally occurring soluble form of mIL-
13R
 
 
 
2 protein in serum may facilitate this function (16).
The complex relationship between the receptor chains of
IL-4 and IL-13 represents a functionally important but
poorly understood mechanism in the regulation of Th2 re-
sponses. In this issue, Wood et al. (17) and Chiaramonte et
al. (18) present compelling evidence for IL-13R
 
 
 
2 acting
as a decoy receptor and thereby regulating the magnitude
of Th2 responses.
 
IL-13R
 
 
 
2–deficient Mice.
 
Wood et al. (17) have gener-
ated an IL-13R
 
 
 
2–deficient mouse line to study the im-
pact deletion this molecule has on immune function. Sig-
nificantly, naive IL-13R
 
 
 
2
 
    
 
animals provide the first
formal evidence for IL-13R
 
 
 
2 acting as a decoy receptor
in vivo. Consistent with IL-13R
 
 
 
2 being a decoy receptor,
the IL-13R
 
 
 
2
 
    
 
mice exhibit phenotypic similarities to
transgenic mice engineered to overexpress IL-13, including
elevated IgE and reduced levels of macrophage-derived IL-
12 (19, 20). There are differences, however, notably the in-
creases in the IgA, IgG2a, and IgG2b in the IL-13R
 
 
 
2
 
   
 
mice. Importantly, because these data are from naive mice
they imply that expression of the IL-13R
 
 
 
2 chain is re-
quired for regulating even the basal level of IL-13 activity.
The article also raises some intriguing questions regarding
the role of IL-13R
 
 
 
2 in regulating the levels of circulating
and tissue IL-13. Interestingly, Wood et al. (17) report that
naive IL-13R
 
 
 
2
 
    
 
mice have greatly reduced levels of se-
rum IL-13 when compared with IL-13R
 
 
 
2
 
    
 
mice. By
contrast, levels of IL-13 were significantly elevated in lung
and liver tissues of IL-13R
 
 
 
2
 
    
 
 mice compared with IL-
13R
 
 
 
2
 
    
 
mice. In an accompanying article in this issue,
Chiaramonte et al. (18) also report on the regulation of IL-
13 by IL-13R
 
 
 
2. An important feature of this study was
that by adding exogenous IL-13R
 
 
 
2-Fc, the authors in-
duced a huge increase in the levels of serum IL-13 (18). It
is clear that the presence or absence of IL-13R
 
 
 
2 not only
profoundly modulates the levels of IL-13, but also appar-
ently influences its distribution between serum and tissues,
raising the question of how this decoy receptor is working.
Previous experiments with cell lines have indicated that
overexpression of IL-13R
 
 
 
2 at the cell surface is capable of
making the cells unresponsive to IL-13 activation (21, 22).
However, two pieces of information presented in the arti-
cles in this issue imply that soluble IL-13R
 
 
 
2 is also re-
sponsible for regulating the levels of serum IL-13. First, in
the naive mice, the absence of IL-13R
 
 
 
2 resulted in a
marked decrease in the levels of circulating IL-13 but high
levels of IL-13 in the tissues (17). This may indicate that
the decoy receptor acts as a carrier for IL-13, however, the
consequences of this interaction are not clear because
ligand/receptor binding may serve to facilitate ligand pres-
ervation or destruction. Second, it is noteworthy that treat-
ment with the soluble IL-13R
 
 
 
2-Fc antagonist also re-
sulted in an increase in circulating IL-13 (18). However, in
this case it is unclear how the presence of the Fc domain al-
ters the function of the native IL-13R
 
 
 
2 molecule because
Figure 1. Schematic represen-
tation of IL-13 and IL-4 receptors.T
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the Fc domain has been shown to slow in vivo clearance of
TNFR-Fc fusion proteins. Now that this novel regulatory
role for IL-13R
 
 
 
2 has been identified, it will be important
to address the mechanism by which this receptor is differ-
entially modulating the levels of circulatory or tissue IL-13.
 
Potential Role for IL-13R
 
 
 
2 in Managing IL-13–induced Fi-
brosis.
 
Chiaramonte et al. (18) have followed up studies
on IL-4 and IL-13 receptor expression during schistosome
infection by assessing the responses of IL-13R
 
 
 
2
 
    
 
mice
to 
 
Schistosoma mansoni
 
 infection. Murine schistosome infec-
tions permit studies on many of the pathogenic processes
that occur in human disease, including hepatic fibrosis and
granuloma formation (Fig. 2) in response to CD4
 
  
 
T cells
and type 2 cytokines (23). Previous studies by our laborato-
ries, in which we infected IL-4
 
   
 
, IL-13
 
   
 
, and IL-4/IL-
13
 
    
 
mice with 
 
S. mansoni
 
, have clearly demonstrated that
in the absence of either IL-4 or IL-13 the reciprocal cyto-
kine is able to compensate for the other, generating almost
all of the pathology observed after infection (24). Most im-
portantly, however, only in the absence of IL-13 was he-
patic fibrosis severely impaired. Similar findings using an
IL-13 antagonist have also been reported (25). Chiara-
monte et al. (18) demonstrate a complementary result,
whereby infection of IL-13R
 
 
 
2
 
    
 
mice with 
 
S. mansoni
 
led to markedly elevated hepatic fibrosis when compared
with infected wild-type animals. Their data also suggest
that IL-13 induces IL-13R
 
 
 
2 expression, suggesting the
presence of a feedback mechanism to prevent excessive IL-
13–induced fibrosis. Importantly, Chiaramonte et al. (18)
did not find differences in a broad number of other patho-
logical features associated with murine schistosome infec-
tion. Thus, these data infer a novel and specific role for IL-
13R
 
 
 
2 in suppressing IL-13–induced fibrosis caused by
schistosome infection. Previous studies have shown that IL-
13 may mediate fibrosis through at least two distinct path-
ways, acting directly on fibroblasts (Fig. 3) or by regulating
other profibrotic factors (26). It will be interesting to deter-
mine, using models such as bleomycin-induced pulmonary
Figure 2. Fibrosis (stained in blue) surrounding an S.
mansoni egg in the liver.
Figure 3. Schematic representation of IL-13R 2 acting as a decoy re-
ceptor to attenuate IL-13–induced fibrosis.T
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fibrosis, the relative contribution of such pathways to the
fibrosis reported in the IL-13R
 
 
 
2
 
    
 
mice. Furthermore,
Th2 cells play a central role in regulating the clinical mani-
festations of allergic disease and mouse models of allergic
airways disease have been used to provide insights into
these processes. Given the results obtained from the analysis
of IL-13R
 
 
 
2
 
    
 
mice infected with 
 
S. mansoni
 
, it will be
important to evaluate the potential role played by IL-
13R
 
 
 
2 in pulmonary allergic disease, particularly in the
context of mucus production and fibrosis.
 
Therapeutic Implications.
 
Soluble forms of many of the
Th2 cytokine receptors have been identified in serum or
urine, but their functional importance remains unclear. It
has been suggested that the soluble receptors may act as an-
tagonists of cytokine function and thereby limit the extent
of ligand-induced activation. However, in some instances,
for example IL-6R
 
 
 
, soluble receptors are in fact agonists
(27). Indeed, experiments in which the administration of
soluble IL-13R
 
 
 
1 was found to up-regulate the expression
of IgM, IgG2a, and IgG2b from germinal center B cells
may also suggest that this IL-13R subunit might act as an
agonist (28). By contrast, IL-13R
 
 
 
2 appears to have
evolved to specifically inhibit the IL-13–mediated func-
tions, though in the present schistosome infection study
only an affect on fibrosis has been described. Blocking of
cytokine functions, either using engineered ligands, recep-
tors, or specific antibodies, is an attractive therapeutic strat-
egy. IL-13 expression correlates strongly with the occur-
rence of allergic asthma and atopy and the associated
expression of IgE (29). Recent studies using mouse models
of experimental airway hypersensitivity have also demon-
strated that IL-13 plays a central role in these responses, in-
dependent of IgE and eosinophilia (1, 2). Thus, inhibiting
IL-13 responses may have tangible clinical benefits. To this
end, a number of IL-13 antagonists have been described.
Due to IL-4R
 
  
 
being part of both the IL-4R complex and
the IL-13R complex, mutant IL-4 analogs that act as com-
petitive antagonists of IL-4 also compete with IL-13 for in-
teraction with the IL-4R
 
 
 
. A mouse IL-4 mutant protein
with amino acid substitutions of Q116D and Y119D forms
unproductive complexes with IL-4R
 
  
 
and is an in vitro
antagonist of IL-4 and IL-13 (30). Similarly, a human IL-4
homologue with a mutation of Y124D competes with both
IL-4 and IL-13 and antagonizes B cell responses (31). In
addition, antibody to IL-4R
 
  
 
inhibits the action of both
IL-4 and IL-13 (32). A more comprehensive understanding
of the roles of the different IL-13 receptor chains in vivo, as
indicated by the studies in this issue, will complement the
ongoing search for IL-13 antagonists. To date, a recombi-
nant soluble IL-13R
 
 
 
2-Fc fusion protein has proven
highly effective in inhibiting IL-13–induced responses (1,
2, 5, 15, 25) and a high affinity IL-13 cytokine trap, bring-
ing together the IL-4R
 
  
 
and IL-13R
 
 
 
1, has also been re-
ported (33).
The reasons for inappropriate Th1 or Th2 responses are
complex but involve dysregulation of mechanisms that
normally control cytokine levels. In the absence of these
regulatory processes life-threatening disease pathology may
 
arise. A number of regulatory processes, including decoy
receptors (e.g., IL-1 type II receptor), have been described
that limit Th1 proinflammatory cytokines. It is now evi-
dent that decoy receptors may also limit Th2 responses and
thus provide an important mechanism for the regulation of
serum and tissue levels of Th2 cytokines. IL-13 decoy re-
ceptors may function to protect against uncontrolled Th2
inflammatory responses and thereby help in maintaining
the balance between Th1 and Th2 pathology.
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